Preview

PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology

Advanced search

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer

https://doi.org/10.17749/2070-4909.2018.11.4.016-027

Full Text:

Abstract

Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC). enzalutamide and abiraterone are the only two hormonal drugs increasing survival and approved for the treatment of mCRPC patients in Russia. The aim of the current study was to develop a pharmacoeconomic tool that calculates direct medical costs (price of the drugs) of using enzalutamide or abiraterone for treatment of chemotherapy-naïve patients with mCRPC from the Russian regional healthcare systems perspective. Materials and methods. The calculator is based on a published pharmacoeconomic model of using enzalutamide or abiraterone for the 1st line treatment of mCRPC. Current regional medication prices, which explain the biggest share of direct medical treatment costs, are automatically accounted for 84 Russian regions (except nenetsky AO). The calculator also provides estimates of number of chemotherapy-naïve patients, who are eligible for enzalutamide or abiraterone treatment in each region. Results. Costs of using enzalutamide or abiraterone are almost equal on the federal level, but the differences in the costs between these two medications are higher than 10% in 15 Russian regions. Conclusions. Possible differences in costs of using enzalutamide or abiraterone should be accounted during planning of state procurements on the regional level.

About the Authors

N. A. Avxentyev
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution; Russian Presidential Academy of National Economy and Public Administration
Russian Federation

Nikolay A. Avxentyev – Adviser at the Research Financial Institution of the Ministry of Finance; Research Fellow at the Institute of Social Analysis and Forecast of the Russian Academy of National Economy and Public Administration;

Researcher ID: O-5364-2018; Scopus Author ID: 57197865322;

3-2 Nastasyinsky pereulok, Moscow 127006;

82 Vernadskogo prospect, Moscow 119571



A. S. Makarov
Interregional Public Organization “Association of Clinical Pharmacologists”
Russian Federation

Alexander S. Makarov – Research Fellow;

1 pl. Pavshikh Bortsov, Volgograd 400131



M. Yu. Frolov
Interregional Public Organization “Association of Clinical Pharmacologists”; Volgograd State Medical University of the Ministry of Health of the Russian Federation
Russian Federation

Maxim Yu. Frolov – MD, PhD, Assistant Professor at the Department of Clinical Pharmacology, Volgograd National Medical University; Executive Director at the Interregional Association of Clinical Pharmacologists;

Researcher ID: O-5364-2018; Scopus Author ID: 57197865322;

1 pl. Pavshikh Bortsov, Volgograd 400131



References

1. Mortality by causes of death in 2017. Rosstat (in Russian). [Electronic resource] URL: http://www.gks.ru/free_doc/new_site/population/demo/demo24-2.xls. Accessed: 05.10.2018.

2. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Edited by A. D. Kaprina, V. V. Starinsky, G. V. Petrova. Moscow. 2018; 250 s. (in Russian).

3. Clinical recommendations: prostate cancer. Association of Oncologists of Russia (in Russian). [Electronic resource] URL: http://oncology-association.ru/files/clinical-guidelines_adults/rak_predstatelnoy_zhelezy.pdf. Accessed: 05.10.2018.

4. Instructions for the medical use of the drug KSOFIGO. State register of medicines (in Russian). [Electronic resource] URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ca833164-d533-4dae-8b94-d6fdee7465d9&t=. Accessed: 05.10.2018.

5. Tannock I. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. new england Journal of Medicine. 2004; 351 (15): 1502-1512.

6. De Bono J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet. 2010; 376 (9747): 1147-1154.

7. Ryan C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. new england Journal of Medicine. 2013; 368 (2): 138-148.

8. Rathkopf D. E. et al. Updated interim efficacy analysis and longterm safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior 34 chemotherapy (COU-AA-302). european urology. 2014; 66 (5): 815- 825.

9. Ryan C. J. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebocontrolled phase 3 study. The Lancet Oncology. 2015; 16 (2): 152-160.

10. De Bono J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. new england Journal of Medicine. 2011; 364 (21): 1995-2005.

11. Fizazi K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The lancet oncology. 2012; 13 (10): 983-992.

12. Scher H. I. et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. new england Journal of Medicine. 2012; 367 (13): 1187-1197.

13. Beer T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. n engl J Med. 2014; 371 (5): 424-433.

14. Beer T. M. et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castrationresistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. european Urology. 2017; 71 (2): 151-154.

15. Kolbin A. S., Kurylev A. A., Pavlysh A. V. Comparison of clinicaleconomic evaluation of cabazitaxel and abiraterone for prostate cancer based on the results of clinical trials and real world data.kachestvennaya klinicheskaya praktika. 2015; (1): 18-31 (In Russian).

16. Avksentyev N. A., Derkach E. V. Pharmacoeconomic analysis of abiraterone for treatment of patients with metastatic castrate-resistant prostate cancer. Medicinskie texnologii. Ocenka i vybor. 2016; 25 (3): 54-67 (In Russian).

17. Avxentyev N. A., Frolov M. Y., Makarov A. S. Pharmacoeconomic analysis of enzalutamide and abiraterone for treatment of chemotherapy naive patients with metastatic castration resistant prostate cancer. Cancer Urology. 2017; 13 (3): 76-86. (In Russian). https://doi.org/10.17650/1726-9776-2017-13-3-76-86.

18. Mazina N. K., Mazin P. V. Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in postdocetaxel castration-resistant prostate cancer patients. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya / Farmakoekonomika. Modern pharmacoeconomics and pharmacoepidemiology. 2017; 10 (3): 12-21. (In Russian). https://doi.org/10.17749/2070-4909.2017.10.3.012-021.

19. Avksentyev N. A., Derkach E. V., Makarov A. S. Pharmacoeconomic evaluation of enzalutamide, abiraterone and cabazitaxel for the treatment of post-chemotherapy patients with metastatic castrationresistant prostate cancer. Medicinskie texnologii. Ocenka i vybor. 2018; 3 (33): 62-74.

20. Data on the limits of wholesale mark-ups and the limits of retail mark-ups on the prices of vital and essential drugs established in the constituent entities of the Russian Federation (data for the 3rd quarter of 2017) (in Russian). FAS Russia. [Electronic resource] URL: https://fas.gov.ru/documents/665519. Accessed: 06.10.2018.

21. Kirby M., Hirst C., Crawford E. D. Characterising the castrationresistant prostate cancer population: a systematic review. International Journal of Clinical Practice. 2011; 65 (11): 1180-1192.


For citation:


Avxentyev N.A., Makarov A.S., Frolov M.Y. Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2018;11(4):16-27. (In Russ.) https://doi.org/10.17749/2070-4909.2018.11.4.016-027

Views: 23


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)